# Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

> **NCT02947022** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 1 (actual)

## Conditions studied

- Headache
- Cognitive Disturbance
- Skin Hyperpigmentation
- Arthralgia

## Interventions

- **DRUG:** Calcium DTPA
- **DRUG:** Zinc DTPA

## Key facts

- **NCT ID:** NCT02947022
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-01-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** PI left institution.
- **Last updated:** 2018-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947022, "Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02947022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*